This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Discussing the FORTIFY phase 3 clinical trial data of BridgeBio's BBP-418 in Limb-girdle Muscular Dystrophy (LGMD2I/R9).

Ticker(s): BBIO, SRPT

Who's the expert?

Institution: Ludwig-Maximilians-Universität München (LMU Klinikum)

  • Professor and Specialist in Neurology and Nutritional Medicine at the Friedrich-Baur-Institut, Neurological Clinic and Polyclinic, LMU Klinikum, focusing on neuromuscular diseases.

  • Manages 50 limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) patients

  • Serves as a key leader in clinical care and education, mentoring neurology residents and coordinating multidisciplinary teams for rare neuromuscular disorders. Leads research on therapeutic strategies for neuromuscular conditions, with over 100 publications advancing patient management in neurology.

Interview Goal
To discuss the current treatment landscape and the potential of BBP-418, a Small Molecule being developed by BridgeBio for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.